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Positron emission tomographyObjective: Silent myocardial ischemia is common in asymptomatic subjects without a prior history of coronary
artery disease (CAD) and is associated with increased morbidity and mortality. Our objective was to determine
whether endothelial dysfunction is associated with silent myocardial ischemia and whether the association is
independent of genetic and familial factors.
Material and methods: We examined 416 male monozygotic and dizygotic twins aged 47 to 63 years, free of
symptomatic CAD. Subclinical ischemia was diagnosed by [13N] ammonia positron emission tomography at
rest and after adenosine stress. Endothelial function was measured by ﬂow-mediated dilation (FMD) of the
brachial artery. Generalized estimating equations were used for analysis.
Results: Fixed perfusion defects were found in 24 (6%) twins and reversible perfusion defects in 90 (22%) twins,
indicating subclinical ischemia. There was an inverse correlation between FMD and the reversible perfusion
defect score (r =−0.14, p = 0.01) but not the ﬁxed defect score (r =−0.017, p = 0.73). From the lowest to
the highest quartiles of FMD, the prevalence of reversible defects decreased from 28% to 14%, p = 0.008. In
multivariable analysis, reversible defects were signiﬁcantly associated with each quartile of decreasing FMD
(OR = 1.3; 95% 1.1, 2.5). In 54 twin pairs discordant for endothelial dysfunction (FMD ≤ 7% dilation from
baseline), twins with endothelial dysfunction had 9% higher likelihood of having perfusion defects than their
co-twins without endothelial dysfunction (p = 0.041).
Conclusions: Endothelial dysfunction is independently associatedwith silent ischemia and this association is not
confounded by genetic or other shared familial factors.
© 2014 TheAuthors. Published byElsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Normal vascular endothelium, by secreting several mediators
including nitric oxide, promotes arterial vasodilation, prevents throm-
bosis, and has anti-proliferative and anti-inﬂammatory actions.
Dysfunction of the endothelium is characterized by impaired vasodilation
in response to endothelial-speciﬁc agonists that reﬂects abnormalities
in the integrity and function of the vascular endothelium.[1,2] This, ﬂow-mediated dilation; PET,
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land Ltd. This is an open access articledysfunction plays a critical role in the pathogenesis of atherosclerotic
coronary artery disease (CAD) and often precedes development
of structural atherosclerosis [3–7]. Endothelial dysfunction can be
measured by intra-arterial infusion of agonists that promote release of
nitric oxide, such as acetylcholine, but these techniques are invasive
and thus have limited applicability [8]. Flow-mediated dilation (FMD)
of the brachial artery is an ultrasound-based method that allows non-
invasive assessment of vascular nitric oxide release in response to
increased shear stress [9]. FMD correlates with traditional vascular
risk factors and is an independent measure of long term outcomes in
both patients with CAD and in the general population [10–18].
Based on myocardial perfusion imaging, asymptomatic subjects
frequently (20–50%) have perfusion abnormalities suggestive of silent
ischemia [19]. These perfusion abnormalities may be due to either
hemodynamically signiﬁcant coronary stenosis, or occur in the absenceunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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to coronary micro vascular endothelial dysfunction [20]. However,
the relationship between silent myocardial ischemia and peripheral
vascular endothelial dysfunction remains unknown. Such an association
may providemechanistic explanation for theworse long termprognosis
in subjects with endothelial dysfunction, and potentially provide a way
to identify a high risk groupwithin an asymptomatic population. In this
study, we investigated the relationship between peripheral vascular
endothelial dysfunction and silentmyocardial ischemia in asymptomat-
ic middle-aged, male twins without a prior history of CAD, with the
hypothesis that endothelial dysfunction,measured as FMD, will identify
a population at risk of silentmyocardial ischemia diagnosed by positron
emission tomography (PET). Twin studies provide a unique opportunity
to examine the association between risk factors and disease because
twins are matched on shared early environment and genetic factors,
since twin siblings share genes (50% on average if dizygotic (DZ) and
100% if monozygotic (MZ)), maternal, and early familial environmental
factors [21].
2. Material and methods
2.1. Study population
The Emory Twin Studies includes samples recruited in two compan-
ion studies: the Twins Heart Study (THS) and the Stress and Vascular
Evaluation in Twins (SAVEIT). The purpose of these studies was to elu-
cidate the role of psychological, behavioral, and biologic risk factors
for subclinical cardiovascular disease in twins. Both studies recruited
randomly selected samples of middle-aged male MZ and DZ twin
pairs (who were raised in the same household) from the Vietnam Era
Twin (VET) Registry, which includes 7369 male–male twin pairs both
of whom served in the US military during the time of the Vietnam
War [22]. Both studies followed identical procedures, measurements,
and protocols. THS enrolled 180 twin pairs between 2002 and 2006
and SAVEIT included 127 twin pairs enrolled between 2005 and 2010
as previously described [20,23,24]. After excluding the second visit of
a few pairs who participated in both studies, the combined sample
included 281 pairs. Pairs of twins were examined at the same time at
the Emory University General Clinical Research Center, and all data
collection occurred during a 24-hour admission under controlled condi-
tions. Both studies were approved by the Emory Institutional Review
Board, and all twins signed an informed consent. Zygosity information
by means of DNA typing was available for all twin pairs.
2.2. Cardiovascular risk assessment
A medical history and a physical examination were obtained on all
twins. Systolic and diastolic blood pressure was measured by mercury
sphygmomanometer on the right arm with the subject in sitting
position after 10 min of rest. The average of two measurements 5 min
apart was used in the statistical analyses. Venous blood samples were
drawn for the measurement of glucose and lipid proﬁle after an over-
night fast. Direct low-density lipoprotein (LDL) cholesterol was obtain-
ed using homogeneous assays (Equal Diagnostics, Exton, Pennsylvania).
Cigarette smoking was classiﬁed into current smoker (any number of
cigarettes) versus never or past smoker. Diabetes mellitus was deﬁned
as having a fasting glucose level of N126 mg/dl or being treated with
anti-diabetic medications.
2.3. Flow-mediated dilation (FMD)
Endothelium-dependent brachial artery FMDwas determined using
bi-mode ultrasound according to standardized procedures as described
previously [25,26]. Images were obtained with an Acuson 10-mHz line-
ar array transducer and ultrasound system (Mountain View, CA, USA).
We performed imaging with the subject resting supine for at least10 min on a hospital bed in a quiet setting. Optimal brachial artery
images were obtained between 2 and 10 cm above the antecubital
crease. After baseline measurements, a blood pressure cuff was inﬂated
to 200mmHg over the proximal portion of the right forearm for 5 min.
Endothelium-dependent function was determined during the ﬁrst
2 min of release of the cuff [27]. After a 15 min period to re-establish
baseline conditions, endothelium-independent dilation was assessed
with similar procedures before and 3 min after administration of
0.4 mg of sublingual nitroglycerin. Images were digitized online, and
arterial diameters were measured with edge-detection software
(Medical Imaging Applications, Coralville, IA, USA) by an individual
blinded to subject data. Arterial diameter was measured in millimeters
from the leading edge of the intima–lumen interface of the near wall
(echo zone 3) to the leading edge of the lumen–intima interface of the
farwall (echo zone 5), coincidentwith the R-wave on the electrocardio-
gram (i.e. end-diastole). The brachial artery vasodilator response was
quantiﬁed as percentage change in vessel diameter from baseline. In
our laboratory, the mean difference in FMD (%) between two consecu-
tive assessments performed in 11 subjects an average of 8 days apart
was 1.26% (±0.76%), with a Pearson's correlation of 0.75. The mean
difference in the FMD (%) between two readings of the same 11
measurements was 0.82% (±0.48%), with a Pearson's correlation of
0.97.
2.4. Myocardial perfusion
Twins underwent imaging of myocardial blood ﬂowwith PET [13N]
ammonia at rest and following pharmacologic (adenosine) stress. On
the day prior to the PET scan, they abstained from smoking and drinking
alcoholic or caffeinated beverages. All medications were held the
morning of the PET scan.
Initially, a 2–3 mCi dose of [13N] ammonia was injected and a
4-minute static scan was collected and reconstructed without any
corrections to verify subject position. Then, rest and pharmacological
stress (adenosine) ammonia imaging was performed on each subject.
The rest and stress imaging protocols were identical except that
a 4-minute infusion of adenosine (0.14 mg/kg/min) was started
2 min prior to the ammonia injection for the stress imaging session.
20 mCi of [13N] ammonia was injected and a 5-minute, 31 frame
dynamic acquisition was started (12 frames × 5 s, 3 frames × 20 s,
1 frame × 300 s). Data were collected in 47 planes 3.375 mm thick
covering a range of 16 cm for the CTI ECAT 921 camera or in 35
planes, 4.25 mm thick, covering a range of 15 cm for the GE PET-CT
Discovery LS scanner. Immediately after the conclusion of the
dynamic sequence, a 15-min gated (8 equally spaced phased gates)
acquisition was started. The injections of ammonia were separated
by at least 50 min to allow [13N] ammonia from the ﬁrst injection
to decay to a level where it would not interfere with the second
study. Images were reconstructed with ﬁltered back projection
using a Hann ﬁlter cutoff at 1 cycle/cm and included attenuation
correction.
We constructed a summary score describing the number and the
severity of visible perfusion defects across 20 myocardial segments.
In each segment, the defect severity was quantiﬁed on a 4-point scale
(0: normal; 4: absent perfusion) and subsequently summed across the
20 segments to yield a total score. Separate scores were obtained for
the rest (summed rest score) and stress (summed stress score) scans.
The difference between these scores, the summed difference score,
was computed to provide an overall indication of reversible ischemia.
In addition we computed dichotomous indicators of perfusion abnormal-
ities, deﬁned as a summed stress score ≥4 across all 20 segments [28].
2.5. Statistical analysis
Continuous variables were described as mean ± SD and categorical
variables as frequencies (percent). We compared baseline demographic
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(both reversible and ﬁxed) across quartiles of FMD treating the twins
as individuals, while accounting for correlated data usingmixedmodels
or generalized estimating equation (GEE) models. In additional analy-
ses, we examined the Spearman correlation between perfusion scores
and FMD both treated as continuous variables. Next, we analyzed the
relationship between FMD and perfusion defects using mixed model
linear regression analysis adapted for twin studies [29]. We treated
perfusion defects as an outcome for these models using dichotomous
categorization (normal or abnormal based on a score ≥4). We then
adjusted for cardiovascular risk factors that include age, body mass
index (BMI), high, total, and low density lipoprotein cholesterol, current
smoking, systolic blood pressure, fasting plasma glucose and history of
major depression. In a separate model we accounted for cardiovascular
risk factors, use of aspirin and statins, as well as anti-hypertensive
medications, including beta blockers, ace-inhibitors, diuretics, and
angiotensin receptor blockers. Potential multicollinearity was investi-
gated using condition indexes and variance decomposition proportions
bymeans of a SASmacro including both a condition index of N20 and at
least 2 non-intercept variables with variable decomposition proportion
values of N0.05.
We next analyzed twin pairs discordant for endothelial dysfunction
where one member had endothelial dysfunction and his twin brother
did not. The highest quartile of hyperemia dilation (N7%) compared to
lower quartiles was used to categorize endothelial dysfunction as
normal vs abnormal. This within-pair analysis automatically takes into
account shared familial and many early environmental factors.
Within-pair analysis was further stratiﬁed by zygosity to determine
whether the relationship between reversible defects and FMD was
different between monozygotic and dizygotic twins. The analysis of
within-pair differences in monozygotic twins is fully controlled for
genetic factors shared between FMD andmyocardial ischemia. Dizygot-
ic twins share on average 50% of genes and differences among the twins
are only partially controlled for shared genetic factors. Shared genetic
factors would be indicated if the within-pair difference in reversible
defects in endothelial dysfunction-discordant pairs is smaller in
monozygotic than in dizygotic pairs. All statistical analyses were
conducted using SAS software, version 9.2 (SAS Institute Inc., NC).
Signiﬁcance level was set at 0.05, two-sided.
3. Results
From the initial sample of 281 twin pairs (562 subjects), we exclud-
ed 65 twins because of previous history of CAD. Furthermore, 81 twins
were excluded because ofmissingdata on PET or FMDdue to scheduling
conﬂicts or technical problems with the imaging equipment orTable 1
Cardiovascular risk factors according to FMD quartiles.
FMD quartiles
Cardiovascular
risk factors
1st
(b2.7%)
2nd
(2.7–4.6%
N 110 97
Age (mean ± s.e) 55.6 ± 2.9 55.3 ± 3
Systolic BP, mm Hg (mean ± s.e) 132.8 ± 14.4 133.6 ±
BMI, kg/m2 (mean ± s.e) 29.4 ± 4.9 29.6 ± 4
Current smoking (%) 29.0 22.0
Alcohol (no. drinks/week) 5.6 ± 9.6 6.6 ± 12.
LDL cholesterol, mg/dl (mean ± s.e) 122.3 ± 32.7 131.0 ±
History of hypertension (%) 23.6 25.0
History of diabetes (%) 37.1 28.9
Taking beta-blockers (%) 28.6 28.5
Taking diuretics (%) 18.5 37.0
Taking statins (%) 24.1 20.4
Taking ACE-inhibitors (%) 22.2 20.3
Taking aspirin (%) 26.9 25.4
FMD = ﬂow mediated dilation; BMI = body mass index; LDL = low density lipoprotein.processing. The ﬁnal sample of 416 twins (mean age 55 years, range
47 to 63 years) was 94% white and 3% black, 64% MZ and 36% DZ, a
distribution that is similar to that of the Vietnam Era Twin Registry.
Therewere no signiﬁcant differences in demographic variables between
MZ and DZ twins. Twins in the higher FMD quartiles had lower systolic
blood pressure and alcohol consumption; no other signiﬁcant differ-
ences were noted (Table 1).
Fixed perfusion defects were observed in 24 (6%), and reversible
perfusion defects in 90 (22%) twins. The summed stress score, but not
the rest score, tended to be lower in twins with higher FMD, and the
summed difference score was negatively correlated with FMD quartiles
(Table 2).When stress perfusionwas dichotomized as normal or abnor-
mal based on a score≥4, twins in the highest quartile of FMDhad lower
prevalence of stress defects compared with twins in the lower FMD
quartiles. Thus, from the lowest to the highest quartile of FMD, the
prevalence of reversible defects decreased from 28% to 14% (p for
trend = 0.008). In contrast, there was little difference in ﬁxed defects
based on endothelial function. Similarly, when FMD was treated as a
continuous variable, it was negatively correlated with the reversible
perfusion defect score (Spearman r =−0.14, p = 0.01,) but not the
ﬁxed defect score (Spearman r =−0.017, p = 0.73).
In the unadjusted model, subjects in the lowest FMD quartile
exhibited twice the odds of myocardial ischemia (presence of reversible
perfusion defects) (OR = 2.0, 95% CI 1.6–2.7) compared with the
highest quartile (Table 3) This association was only mildly diminished
after adjusting for age, smoking, BMI, systolic blood pressure, plasma
lipids and fasting glucose. There was no association between FMD and
ﬁxed defects.
Our ﬁnal analyses focused on twin pairs who were discordant for
endothelial dysfunction (deﬁned as FMD ≤ 7% dilation from baseline
diameter), i.e. where one member had endothelial dysfunction and his
twin brother did not. In 54 discordant twin pairs, twinswith endothelial
dysfunction had 9% higher likelihood to have perfusion defects than
their co-twins without endothelial dysfunction (p = .041). Results for
MZ and DZ twin pairs were similar.
4. Discussion
In asymptomatic subjects without a prior history of CAD, endothelial
dysfunction, as demonstrated by reduced FMD, is independently
associated with inducible myocardial ischemia. This relationship
remained signiﬁcant even after adjustment for traditional CAD risk
factors. These ﬁndings were conﬁrmed in twin pairs discordant for
endothelial dysfunction, where those with endothelial dysfunction
were more likely to have reversible perfusion defects than their co-
twins (bothmonozygotic and dizygotic)without endothelial dysfunction.)
3rd
(4.6–7.0%)
4th
(N7%)
p-Value
for trend
107 102
.16 55.5 ± 3.16 54.8 ± 3.6 0.12
16.5 127.5 ± 15.1 127.7 ± 15.0 0.02
.5 29.4 ± 4.3 29.7 ± 5.8 0.71
27.0 22.0 0.34
6 3.5 ± 5.2 3.5 ± 5.7 0.03
35.5 122.2 ± 31.2 119.8 ± 31.2 0.29
26.4 25.0 0.78
34.3 25.7 0.95
28.6 14.2 0.20
14.8 29.6 0.83
27.7 27.7 0.47
33.3 24.1 0.57
29.4 18.3 0.13
Table 2
Myocardial perfusion imaging data by FMD quartile.
FMD Quartiles
Myocardial perfusion
scores
1st
(b2.7%)
2nd
(2.7–4.6%)
3rd
(4.6–7.0%)
4th
(N7%)
p-Value
for trend
N 110 97 107 102
Summed stress score, mean ± SD 2.26 ± 5.2 2.12 ± 6.2 1.85 ± 3.6 1.22 ± 3.2 0.06
Summed rest score, mean ± SD 0.51 ± 2.1 0.62 ± 2.6 0.45 ± 2.0 0.45 ± 1.5 0.64
Summed difference score, mean ± SD 1.7 ± 4.9 1.5 ± 4.7 1.4 ± 2.8 0.7 ± 2.1 0.04
Abnormal stress perfusiona, N (%) 39 (27) 41 (29) 36 (25) 24 (17) 0.007
Fixed defectsb, N (%) 10 (24) 12 (27) 10 (24) 10 (24) 0.82
Reversible defectsc, N (%) 29 (28) 28 (26) 26 (25) 14 (14) 0.008
a Summed stress score ≥4.
b Summed rest score ≥4.
c Summed difference score ≥4.
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ischemia is not confounded by CVD risk factors, shared genetic or other
familial factors. Thus, in asymptomatic individuals without a history of
CAD, endothelial dysfunction is associated with a higher risk of reversible
myocardial ischemia. Our results suggest that endothelial dysfunction
may be implicated in asymptomatic myocardial ischemia.
Endothelial function is an excellent barometer of vascular health [2,
30]. Abnormal endothelial function is associated with greater risk factor
burden and coronary atherosclerosis, and improves in response to anti-
atherosclerotic therapies [31–33]. Coronary endothelial dysfunction
correlates with peripheral endothelial dysfunction and both are
markers of subsequent increased risk of adverse cardiovascular events
in patients with and without established CAD [14,16,34]. Although,
prior studies in CAD patients have linked endothelial dysfunction to
myocardial perfusion defects [35], no previous studies have examined
if this is also true in asymptomatic individuals without prior history of
CAD among whom the etiology of perfusion abnormalities is not
known [36–38]. In our study of asymptomatic, community individuals
without a clinical history of CAD, a lower FMD was associated with a
doubling in risk of silent myocardial ischemia, suggesting that endothe-
lial dysfunction is an important underlying mechanism.
Silent ischemia, deﬁned as myocardial ischemia occurring in the
absence of angina or angina equivalents, is a common yet frequently
unrecognized manifestation of CAD, accounting for more than 75%
of ischemic episodes during daily life [39,40]. Silent ischemia is an
independent predictor of future cardiac events even in patients without
a history of CAD, whether it is detected by exercise testing, ambulatory
electrocardiography, or imaging modalities [41,42]. Importantly, up to
48% of subjects with known CAD and silent ischemia detected by
electrocardiography have an adverse cardiac event within 4 to 6 years
[43,44]. Whether community screening with FMD is of beneﬁt in
reducing the risk of coronary events and cardiac death, however,
needs to be further evaluated.Table 3
Unadjusted and adjusted odds ratios for the relationship between FMD quartiles and
presence of myocardial perfusion defects.
FMD Quartiles
Myocardial
perfusion defects
1st
OR (95% CI)
2nd
OR (95% CI)
3rd
OR (95% CI)
4th p-Value
for trend
Reversible defects
Unadjusted 2.0 (1.6, 2.7) 1.6 (1.2, 2.7) 1.4 (1.1, 2.7) 1.0 0.04
Adjusteda 1.9 (1.6, 2.6) 1.5 (1.2, 2.1) 1.3 (1.1, 2.5) 1.0 0.03
Fixed defects
Unadjusted 1.5 (0.7, 2.9) 1.1 (0.4, 2.6) 1.3 (0.6, 3.1) 1.0 0.51
Ajusteda 1.5 (0.7, 1.1) 1.1 (0.4, 2.6) 1.3 (0.6, 3.1) 1.0 0.50
a Adjusted for age, smoking, body mass index (BMI), systolic blood pressure, plasma
lipids, and fasting plasma glucose.Despite being asymptomatic and without a clinical history of CAD,
22% of our sample had reversible perfusion defects on cardiac PET
perfusion imaging. Consistent with our data, the prevalence of my-
ocardial perfusion abnormalities in asymptomatic subjects has been
reported to be between 20 and 50% and is attributed to the presence
of CAD risk factors and/or family history [19,45,46]. A number of under-
lying mechanisms have been suggested for ischemia being silent,
including subclinical epicardial disease, microvascular dysfunction
[47], blunted pain perception or insufﬁcient degree of ischemia to
stimulate pain receptors. Our ﬁndings suggest that endothelial dysfunc-
tion can play an important pathophysiologic role, independent of
traditional CAD risk factors and family background and provides
mechanistic insight for the link between FMD and coronary heart
disease events [14,34,48,49].
Our study has several strengths.Wehave the advantage of a relative-
ly large sample size and a twin study design. Twins provide naturally
matched pairs where the potential confounding effects of a large
number of factors such as sociodemographic, genetic and other familial
inﬂuences are removed by comparisons within twin pairs. Our study
also had the advantage of detailed measures of CVD risk factors and
lifestyle behaviors. There are also a few limitations. Our analyses are
cross-sectional and thuswe are unable to address the temporal relation-
ship between FMD and silent ischemia. Further, the sample is restricted
to predominantly healthy middle-aged male Vietnam era veterans, and
therefore, our results may not be generalizable to women and may not
extend to younger subjects or populations with clinically manifest
cardiovascular disease. Also we have no coronary angiography data on
these participants to conﬁrm or exclude the presence of obstructive
CAD.
In conclusion, we showed that endothelial dysfunction, as assessed
by means of brachial artery FMD, is independently associated with a
2-fold increased risk of silent ischemia in predominantly healthy
asymptomaticmen, independent of CVD risk factors, and shared genetic
or environmental factors. Our results support growing evidence linking
endothelial dysfunction to the early phases of CAD and point to a key
role of the endothelium in the pathophysiology of myocardial ischemia.
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